Immunomodulatory drugs (IMiDs) are effective in the treatment of multiple myeloma (MM), myelodysplastic syndrome with deletion of chromosome 5q and other haematological malignancies. Recent studies showed that IMiDs bind to cereblon (CRBN), a substrate receptor of the CRL4-CRBN complex, to induce the ubiquitination and degradation of IKZF1 and IKZF3 in MM cells, contributing to their anti-myeloma activity. We aimed to determine whether the CRL4-CRBN complex proteins' expression predicts the prognosis of MM patients treated with IMiDs. Here, we evaluated the expression of CRL4-CRBN complex proteins and their downstream targets with immunohistochemistry (IHC) staining in 130 bone marrow samples from MM patients treated with thalidomide or lenalidomide-based regimens. We found that the expression of CRBN and CUL4A was associated with the superior IMiD-based treatment response ( = 0.007 and = 0.007, respectively). Moreover, the CUL4A expression was associated with improved PFS (HR = 0.66, 95% CI 0.44-0.99; = 0.046) and DDB1 expression showed a negative impact on OS both in the univariate (HR = 2.75, 95% CI 1.65-4.61; = 0.001) and the multivariate (HR 3.67; 95% CI 1.79-7.49; < 0.001) analysis. Overall, our data suggest that the expression of DDB1, CUL4A and CRBN assessed by IHC predicts the clinical course of MM patients and identifies patients with a high probability of responding to IMiD-based therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235391 | PMC |
| http://dx.doi.org/10.3390/jcm10122683 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Arginine methylation-dependent TRIM47 stability mediated by CARM1 promotes the metastasis of hepatocellular carcinoma.
Cell Death Discov
November 2024
Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Wuhan, China.
The tripartite motif (TRIM) protein family has been shown to play important roles in the occurrence and development of various tumors. However, the biological functions of TRIM47 and its regulatory mechanism in hepatocellular carcinoma (HCC) remain unexplored. Here, we showed that TRIM47 was upregulated in HCC tissues compared with adjacent normal tissues, especially at advanced stages, and associated with poor prognosis in HCC patients.
View Article and Find Full Text PDFMechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex.
Commun Chem
August 2024
AbbVie, 1 North Waukegan Rd, North Chicago, IL, 60064, USA.
PTPN2 (protein tyrosine phosphatase non-receptor type 2, or TC-PTP) and PTPN1 are attractive immuno-oncology targets, with the deletion of Ptpn1 and Ptpn2 improving response to immunotherapy in disease models. Targeted protein degradation has emerged as a promising approach to drug challenging targets including phosphatases. We developed potent PTPN2/N1 dual heterobifunctional degraders (Cmpd-1 and Cmpd-2) which facilitate efficient complex assembly with E3 ubiquitin ligase CRL4, and mediate potent PTPN2/N1 degradation in cells and mice.
View Article and Find Full Text PDFIntrinsic signaling pathways modulate targeted protein degradation.
Nat Commun
July 2024
Laboratory of Protein Degradation, Institute for Advanced Life Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.
Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target BRD4 and related neosubstrates BRD2/3 and CDK9 induced by CRL2- or CRL4 -based PROTACs. The chemicals identified as degradation enhancers include inhibitors of cellular signaling pathways such as poly-ADP ribosylation (PARG inhibitor PDD00017273), unfolded protein response (PERK inhibitor GSK2606414), and protein stabilization (HSP90 inhibitor luminespib).
View Article and Find Full Text PDFSingle-domain antibody-based protein degrader for synucleinopathies.
Mol Neurodegener
May 2024
Department of Neuroscience and Physiology, and Neuroscience Institute, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Article Synopsis
- Synucleinopathies are neurodegenerative diseases marked by the buildup of α-synuclein in the brain, causing various motor and psychological symptoms, with no current cures available.
- A new approach using a single-domain antibody (sdAb)-based protein degrader has been developed to promote the breakdown of α-synuclein by targeting both α-syn and a receptor that aids in its degradation.
- This study shows that the sdAb effectively enhances the removal of α-synuclein in laboratory and mouse models, suggesting it could be a promising therapy for synucleinopathies and could lead to improved brain access compared to traditional antibodies.
Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
RSC Med Chem
February 2024
Center for Protein Degradation, Dana-Farber Cancer Institute Boston MA USA
Article Synopsis
- Sulfonyl fluoride EM12-SF was previously designed to target a specific histidine in cereblon (CRBN), part of a complex that regulates protein degradation.* -
- The study discovered that isoindoline EM364-SF, despite missing a crucial bonding feature, effectively binds to CRBN and led to the creation of a reversible molecular glue, CPD-2743.* -
- CPD-2743 demonstrated strong cell-based binding to CRBN, effectively degrading the neosubstrate IKZF1 without causing teratogenic side effects, showcasing advancements in chemical biology and medicinal chemistry design.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!